Nasdaq · Common stock
Avalyn Pharma (AVLN)
$27.14 +$1.10 (+4.22%)
- Day’s range
- $25.48–$28.52
- Volume
- 411,634
AVLN price history
AVLN closed at $27.14 on Oct. 26, 2026. Over the past year, its daily close ranged from $23.33 on Oct. 19, 2026 to $39.25 on Aug. 14, 2026.
Data table: AVLN daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $27.14 |
| Oct. 23, 2026 | $26.04 |
| Oct. 22, 2026 | $27.25 |
| Oct. 21, 2026 | $25.11 |
| Oct. 20, 2026 | $24.63 |
| Oct. 19, 2026 | $23.33 |
| Oct. 16, 2026 | $23.66 |
| Oct. 15, 2026 | $24.64 |
| Oct. 14, 2026 | $23.69 |
| Oct. 13, 2026 | $23.74 |
| Oct. 12, 2026 | $24.80 |
| Oct. 9, 2026 | $25.76 |
| Oct. 8, 2026 | $25.72 |
| Oct. 7, 2026 | $25.53 |
| Oct. 6, 2026 | $25.43 |
| Oct. 5, 2026 | $27.03 |
| Oct. 2, 2026 | $28.13 |
| Oct. 1, 2026 | $27.42 |
| Sept. 30, 2026 | $28.49 |
| Sept. 29, 2026 | $27.10 |
| Sept. 28, 2026 | $28.32 |
| Sept. 25, 2026 | $28.08 |
| Sept. 24, 2026 | $28.55 |
| Sept. 23, 2026 | $29.67 |
| Sept. 22, 2026 | $32.45 |
| Sept. 21, 2026 | $31.62 |
| Sept. 18, 2026 | $31.52 |
| Sept. 17, 2026 | $33.43 |
| Sept. 16, 2026 | $34.71 |
| Sept. 15, 2026 | $34.28 |
| Sept. 14, 2026 | $34.98 |
| Sept. 11, 2026 | $33.57 |
| Sept. 10, 2026 | $34.67 |
| Sept. 9, 2026 | $35.88 |
| Sept. 8, 2026 | $37.62 |
| Sept. 4, 2026 | $37.39 |
| Sept. 3, 2026 | $35.44 |
| Sept. 2, 2026 | $35.58 |
| Sept. 1, 2026 | $35.28 |
| Aug. 31, 2026 | $34.73 |
| Aug. 28, 2026 | $34.69 |
| Aug. 27, 2026 | $36.51 |
| Aug. 26, 2026 | $37.04 |
| Aug. 25, 2026 | $38.20 |
| Aug. 24, 2026 | $37.69 |
| Aug. 21, 2026 | $38.37 |
| Aug. 20, 2026 | $37.13 |
| Aug. 19, 2026 | $38.97 |
| Aug. 18, 2026 | $38.86 |
| Aug. 17, 2026 | $38.25 |
| Aug. 14, 2026 | $39.25 |
| Aug. 13, 2026 | $36.58 |
| Aug. 12, 2026 | $37.38 |
| Aug. 11, 2026 | $35.46 |
| Aug. 10, 2026 | $34.56 |
| Aug. 7, 2026 | $33.92 |
| Aug. 6, 2026 | $32.70 |
| Aug. 5, 2026 | $32.00 |
| Aug. 4, 2026 | $30.73 |
| Aug. 3, 2026 | $28.50 |
| July 31, 2026 | $28.79 |
| July 30, 2026 | $29.31 |
| July 29, 2026 | $28.10 |
| July 28, 2026 | $27.79 |
| July 27, 2026 | $27.62 |
| July 24, 2026 | $27.95 |
| July 23, 2026 | $29.73 |
| July 22, 2026 | $28.72 |
| July 21, 2026 | $29.03 |
| July 20, 2026 | $28.63 |
| July 17, 2026 | $28.30 |
| July 16, 2026 | $25.68 |
| July 15, 2026 | $27.40 |
| July 14, 2026 | $28.28 |
| July 13, 2026 | $27.84 |
| July 10, 2026 | $28.06 |
| July 9, 2026 | $28.92 |
| July 8, 2026 | $28.94 |
| July 7, 2026 | $28.42 |
| July 6, 2026 | $27.65 |
| July 2, 2026 | $29.73 |
| July 1, 2026 | $30.17 |
| June 30, 2026 | $32.92 |
| June 29, 2026 | $31.00 |
| June 26, 2026 | $30.71 |
| June 25, 2026 | $28.98 |
| June 24, 2026 | $30.09 |
| June 23, 2026 | $32.29 |
| June 22, 2026 | $32.97 |
| June 18, 2026 | $31.45 |
| June 17, 2026 | $29.31 |
| June 16, 2026 | $28.07 |
| June 15, 2026 | $28.75 |
| June 12, 2026 | $30.08 |
| June 11, 2026 | $28.07 |
| June 10, 2026 | $28.53 |
| June 9, 2026 | $28.67 |
| June 8, 2026 | $28.06 |
| June 5, 2026 | $27.06 |
| June 4, 2026 | $26.99 |
| June 3, 2026 | $26.40 |
| June 2, 2026 | $25.72 |
| June 1, 2026 | $26.66 |
| May 29, 2026 | $28.78 |
| May 28, 2026 | $28.39 |
| May 27, 2026 | $26.82 |
| May 26, 2026 | $26.70 |
| May 22, 2026 | $28.84 |
| May 21, 2026 | $28.41 |
| May 20, 2026 | $28.03 |
| May 19, 2026 | $28.11 |
| May 18, 2026 | $26.63 |
| May 15, 2026 | $29.84 |
| May 14, 2026 | $30.62 |
| May 13, 2026 | $30.83 |
| May 12, 2026 | $29.90 |
| May 11, 2026 | $29.57 |
| May 8, 2026 | $27.33 |
| May 7, 2026 | $26.93 |
| May 6, 2026 | $27.71 |
| May 5, 2026 | $27.43 |
| May 4, 2026 | $29.07 |
| May 1, 2026 | $29.84 |
| April 30, 2026 | $29.49 |
Key figures
- Average daily volume
- 247,419Past 3 months
- Market value
- $1.20B
- Dividend yield
- —
Price change
- 1 month
- −3.35%
- 3 months
- −2.90%
What Wall Street says about AVLN
In the past 90 days, Wall Street firms published 2 rating or price-target actions on AVLN: 1 new rating and 1 raised price target.
| Action | Rating | |||
|---|---|---|---|---|
| Raymond James | Initiates coverage | Outperform | $60 | |
| Morgan Stanley | Raises target | Overweight | $53 to $57 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
- Headquarters
- Boston, Mass.
- Listed
- April 30, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about AVLN is on the site yet.